Further in vivo studies to decipher the role of STIP1 autoantibodies by investigating its interaction with the STIP1–PrPC complex, the chaperone machinery, and its downstream immunomodulatory effects may unravel novel therapeutic targets for Parkinson’s disease. This evidence concerns the gene PRNP and Parkinson disease.